Dr. Richard Drake received his Ph.D. from the University of Kentucky in Biochemistry and Molecular Biology. He did his Post-doctoral training in Glycobiology with Alan Elbein at the University of Texas Health Science Center at San Antonio, TX. Dr. Drake is currently a Professor at the Medical University of South Carolina in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics and the SmartState Endowed Chair in Proteomics. He has a long research history and expertise in Imaging Mass Spectrometry of tumor tissues and biomarker discovery from clinical fluids, and is currently President of the Imaging Mass Spectrometry Society. His current efforts are in the large scale application of N-glycan Imaging Mass Spectrometry methods developed in his laboratory for prostate, pancreas, liver, kidney, colon, and breast tumors. The goal is to develop glycan biomarkers associated with tumor, stroma, and immune regions of tumors, in two and three dimensions. Dr. Drake is a co-founder of Glycopath, a company that focuses on glycosylation patterns as a prognostic or diagnostic tool.